Harrow (HROW) Share-based Compensation (2010 - 2026)
Harrow (HROW) recorded quarterly Share-based Compensation of $3.8 million in Q1 2026, up 0.97% quarter-over-quarter from $3.8 million in Q4 2025, and down 15.78% on a YoY basis from $4.6 million in Q1 2025.
Harrow (HROW) Share-based Compensation (2010 - 2026) Analysis & Trends
Harrow's Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 15.78% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 34.57% YoY), while the FY2025 annual figure was $12.5 million, down 29.04% from the prior year.
- Share-based Compensation was $3.8 million for Q1 2026 at Harrow, up from $3.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q2 2023 to a low of $875000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $3.4 million across 5 years, with a median of $3.8 million in 2026.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 171.55% in 2023, then slumped 79.51% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $2.0 million in 2022, then soared by 105.36% to $4.2 million in 2023, then climbed by 14.83% to $4.8 million in 2024, then dropped by 20.73% to $3.8 million in 2025, then increased by 0.97% to $3.8 million in 2026.
- The last three Share-based Compensation figures came in at $3.8 million (Q1 2026), $3.8 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 36.86 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.04 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.84 Mn |
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 875,000.00 |
| Mar 31, 2025 | 4.56 Mn |
| Mar 31, 2025 | 4.56 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Dec 31, 2023 | 4.18 Mn |